234 related articles for article (PubMed ID: 28008177)
1. Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia.
Fisher DAC; Malkova O; Engle EK; Miner CA; Fulbright MC; Behbehani GK; Collins TB; Bandyopadhyay S; Zhou A; Nolan GP; Oh ST
Leukemia; 2017 Sep; 31(9):1962-1974. PubMed ID: 28008177
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.
Fisher DAC; Fowles JS; Zhou A; Oh ST
Front Immunol; 2021; 12():683401. PubMed ID: 34140953
[TBL] [Abstract][Full Text] [Related]
3. Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition.
Kong T; Laranjeira ABA; Collins TB; De Togni ES; Wong AJ; Fulbright MC; Ruzinova M; Celik H; Challen GA; Fisher DAC; Oh ST
Blood Adv; 2022 Jan; 6(2):611-623. PubMed ID: 34644371
[TBL] [Abstract][Full Text] [Related]
4. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.
Saenz DT; Fiskus W; Manshouri T; Rajapakshe K; Krieger S; Sun B; Mill CP; DiNardo C; Pemmaraju N; Kadia T; Parmar S; Sharma S; Coarfa C; Qiu P; Verstovsek S; Bhalla KN
Leukemia; 2017 Mar; 31(3):678-687. PubMed ID: 27677740
[TBL] [Abstract][Full Text] [Related]
5. Distinct profile of CD34
Forte D; Barone M; Morsiani C; Simonetti G; Fabbri F; Bruno S; Bandini E; Sollazzo D; Collura S; Deregibus MC; Auteri G; Ottaviani E; Vianelli N; Camussi G; Franceschi C; Capri M; Palandri F; Cavo M; Catani L
J Exp Clin Cancer Res; 2021 Feb; 40(1):49. PubMed ID: 33522952
[TBL] [Abstract][Full Text] [Related]
6. Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.
Yan D; Pomicter AD; Tantravahi S; Mason CC; Senina AV; Ahmann JM; Wang Q; Than H; Patel AB; Heaton WL; Eiring AM; Clair PM; Gantz KC; Redwine HM; Swierczek SI; Halverson BJ; Baloglu E; Shacham S; Khorashad JS; Kelley TW; Salama ME; Miles RR; Boucher KM; Prchal JT; O'Hare T; Deininger MW
Clin Cancer Res; 2019 Apr; 25(7):2323-2335. PubMed ID: 30563936
[TBL] [Abstract][Full Text] [Related]
7. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
8. Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia.
Engle EK; Fisher DA; Miller CA; McLellan MD; Fulton RS; Moore DM; Wilson RK; Ley TJ; Oh ST
Leukemia; 2015 Apr; 29(4):869-76. PubMed ID: 25252869
[TBL] [Abstract][Full Text] [Related]
9. Myelofibrosis in 2019: moving beyond JAK2 inhibition.
Schieber M; Crispino JD; Stein B
Blood Cancer J; 2019 Sep; 9(9):74. PubMed ID: 31511492
[TBL] [Abstract][Full Text] [Related]
10. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
11. Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling.
Fisher DAC; Miner CA; Engle EK; Hu H; Collins TB; Zhou A; Allen MJ; Malkova ON; Oh ST
Leukemia; 2019 Aug; 33(8):1978-1995. PubMed ID: 30718771
[TBL] [Abstract][Full Text] [Related]
12. A case of myeloid sarcoma with correlation to JAK2V617F mutation, complicated by myelofibrosis and secondary acute myeloid leukemia.
Yoshiki Y; Asai T; Ichikawa M; Hangaishi A; Ota S; Imai Y; Takahashi T; Kurokawa M
Intern Med; 2011; 50(21):2649-52. PubMed ID: 22041374
[TBL] [Abstract][Full Text] [Related]
13. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
[TBL] [Abstract][Full Text] [Related]
14. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
15. CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis.
Dunbar AJ; Kim D; Lu M; Farina M; Bowman RL; Yang JL; Park Y; Karzai A; Xiao W; Zaroogian Z; O'Connor K; Mowla S; Gobbo F; Verachi P; Martelli F; Sarli G; Xia L; Elmansy N; Kleppe M; Chen Z; Xiao Y; McGovern E; Snyder J; Krishnan A; Hill C; Cordner K; Zouak A; Salama ME; Yohai J; Tucker E; Chen J; Zhou J; McConnell T; Migliaccio AR; Koche R; Rampal R; Fan R; Levine RL; Hoffman R
Blood; 2023 May; 141(20):2508-2519. PubMed ID: 36800567
[TBL] [Abstract][Full Text] [Related]
16. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.
Oh ST; Gotlib J
Expert Rev Hematol; 2010 Jun; 3(3):323-37. PubMed ID: 21082983
[TBL] [Abstract][Full Text] [Related]
17. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
Pardanani A; Tefferi A
Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
[TBL] [Abstract][Full Text] [Related]
18. [Myeloproliferative diseases caused by JAK2 mutation].
Nagata K; Shimoda K
Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
[TBL] [Abstract][Full Text] [Related]
19. Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion.
Heaton WL; Senina AV; Pomicter AD; Salama ME; Clair PM; Yan D; Bell RN; Gililland JM; Prchal JT; O'Hare T; Deininger MW
Leukemia; 2018 Nov; 32(11):2399-2411. PubMed ID: 29749399
[TBL] [Abstract][Full Text] [Related]
20. A p53-JAK-STAT connection involved in myeloproliferative neoplasm pathogenesis and progression to secondary acute myeloid leukemia.
Goyal H; Chachoua I; Pecquet C; Vainchenker W; Constantinescu SN
Blood Rev; 2020 Jul; 42():100712. PubMed ID: 32660739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
